AIDS 2021 Jul 13. Epub 2021 Jul 13.
University of Nebraska Medical Center, Omaha, NE, United States Infektiologikum, Frankfurt, Germany The Aurum Institute, Pretoria, South Africa Fundación IDEAA, Buenos Aires, Argentina Hannover Medical School (MHH), Hannover, Germany Newtown Clinical Research Centre, Johannesburg, South Africa University at Buffalo Jacobs school of Medicine and Biomedical Sciences, Buffalo, NY, United States ViiV Healthcare, Brentford, United Kingdom GlaxoSmithKline, Mississauga, Ontario, Canada ViiV Healthcare, Research Triangle Park, NC, United States GlaxoSmithKline, London, United Kingdom GlaxoSmithKline, Research Triangle Park, NC, United States Janssen Research & Development, Beerse, Belgium Brii Biosciences, Durham, NC, United States.
Background: ATLAS (NCT02951052), a Phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) + rilpivirine (RPV) long-acting (LA) dosed every 4 weeks was noninferior at Week (W) 48 to continuing three-drug daily oral antiretroviral therapy (CAR). Results from the W96 analysis are presented.
Methods And Design: Participants completing W52 of ATLAS were given the option to withdraw, transition to ATLAS-2 M (NCT03299049), or enter an Extension Phase (EP) to continue LA therapy (LA arm) or switch from CAR to LA therapy (Switch arm). Read More